TNFRSF4 and ovarian carcinoma: Although antagonist PD-1 or agonistic OX40 antibodies can promote the rejection of some murine tumors, however, poorly immunogenic tumors such as ID8 ovarian cancer do not respond to antibody therapy alone [35].